RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Jill Bargonetti to Proto-Oncogene Proteins c-mdm2

This is a "connection" page, showing publications Jill Bargonetti has written about Proto-Oncogene Proteins c-mdm2.
  1. Gao C, Xiao G, Piersigilli A, Gou J, Ogunwobi O, Bargonetti J. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells. Breast Cancer Res. 2019 01 14; 21(1):5.
    View in: PubMed
    Score: 0.647
  2. Loo LWM, Gao C, Shvetsov YB, Okoro DR, Hernandez BY, Bargonetti J. MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population. Breast Cancer Res Treat. 2019 Feb; 174(1):257-269.
    View in: PubMed
    Score: 0.640
  3. Kundu N, Brekman A, Kim JY, Xiao G, Gao C, Bargonetti J. Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway. Oncotarget. 2017 Jul 18; 8(29):47916-47930.
    View in: PubMed
    Score: 0.583
  4. Rosso M, Polotskaia A, Bargonetti J. Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death. Oncotarget. 2015 Oct 27; 6(33):34573-91.
    View in: PubMed
    Score: 0.518
  5. Rosso M, Okoro DE, Bargonetti J. Splice variants of MDM2 in oncogenesis. Subcell Biochem. 2014; 85:247-61.
    View in: PubMed
    Score: 0.456
  6. Okoro DR, Arva N, Gao C, Polotskaia A, Puente C, Rosso M, Bargonetti J. Endogenous human MDM2-C is highly expressed in human cancers and functions as a p53-independent growth activator. PLoS One. 2013; 8(10):e77643.
    View in: PubMed
    Score: 0.449
  7. Brekman A, Singh KE, Polotskaia A, Kundu N, Bargonetti J. A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res. 2011 Jan 11; 13(1):R3.
    View in: PubMed
    Score: 0.371
  8. Arva NC, Talbott KE, Okoro DR, Brekman A, Qiu WG, Bargonetti J. Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes. Ethn Dis. 2008; 18(2 Suppl 2):S2-1-8.
    View in: PubMed
    Score: 0.301
  9. White DE, Talbott KE, Arva NC, Bargonetti J. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. Cancer Res. 2006 Apr 01; 66(7):3463-70.
    View in: PubMed
    Score: 0.267
  10. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem. 2005 Jul 22; 280(29):26776-87.
    View in: PubMed
    Score: 0.063
  11. Xiao G, Chicas A, Olivier M, Taya Y, Tyagi S, Kramer FR, Bargonetti J. A DNA damage signal is required for p53 to activate gadd45. Cancer Res. 2000 Mar 15; 60(6):1711-9.
    View in: PubMed
    Score: 0.044
  12. Xiao G, White D, Bargonetti J. p53 binds to a constitutively nucleosome free region of the mdm2 gene. Oncogene. 1998 Mar 05; 16(9):1171-81.
    View in: PubMed
    Score: 0.038
  13. Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, Reynoso K, Bargonetti J, Wellstein A, Albanese C, Avantaggiati ML. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle. 2012 Dec 01; 11(23):4436-46.
    View in: PubMed
    Score: 0.026
  14. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004 Nov 24; 119(5):591-602.
    View in: PubMed
    Score: 0.015
  15. Hui L, Abbas T, Pielak RM, Joseph T, Bargonetti J, Foster DA. Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53. Mol Cell Biol. 2004 Jul; 24(13):5677-86.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support